SQLite Web: event_store.db

Update row 54785 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-16T02:08:52.472606+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:a55198e3a6424a46","evidence_event_ids":["evt_87744e9226c5"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003477.txt","as_of":"2026-04-16T02:08:52.472606+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003477.txt","company":"Travere Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003477.txt","article_chars":2066,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_8ec0b62c87ddd377","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003477.txt","content_type":"text/plain","enriched_at":"2026-04-16T02:48:53.530207+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003477.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003477.txt","source_event_id":"evt_87744e9226c5","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"fd9907a930d63d61","kind":"sec_filing","published_at":"20260415","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-15","2026-04-13","2026-04-14","2026-02-04","2026-02-03","2025-05-28","2013-02-20","2008-06-25"],"entities":[{"asset_class":"equity","name":"Travere Therapeutics, Inc.","relevance":"high","symbol":"TVTX","type":"issuer"},{"asset_class":"person","name":"Jula Inrig","relevance":"high","symbol":"","type":"reporting-owner"},{"asset_class":"broker","name":"Morgan Stanley Smith Barney LLC","relevance":"medium","symbol":"","type":"broker"}],"event_type":"listing","information_gaps":["The signal does not provide the prior known state, so the specific 'delta' versus earlier filings cannot be determined from the provided text alone.","Form 144 typically includes detailed sale/disposition amounts; while the text shows multiple lines with dates and numeric fields, the exact mapping of each numeric value to shares vs. price vs. aggregate amount is not explicitly labeled in the provided excerpt.","No explicit statement of total shares to be sold or remaining shares is included in the provided text beyond the listed transaction lines."],"key_facts":["SEC accession number: 0001950047-26-003477.","Conformed submission type: Form 144.","Filed as of date: 2026-04-15 (DATE AS OF CHANGE: 2026-04-15).","Subject company/conformed name: Travere Therapeutics, Inc. (CIK: 0001438533).","Reporting-owner: Inrig Jula (CIK: 0001902368).","Filing lists transactions for common stock with dates including 04/15/2026, 04/13/2026, 04/14/2026, 02/04/2026, and 02/03/2026.","Document text shows a broker line: Morgan Stanley Smith Barney LLC (New York Plaza address).","The filing includes a signature: /s/ Jula Inrig, dated 05/28/2025 (as shown in the text)."],"numeric_claims":[{"label":"Transaction price (shown)","value":"43376.98"},{"label":"Shares/quantity (shown)","value":"92241550"},{"label":"Transaction price (shown)","value":"302516.29"},{"label":"Transaction price (shown)","value":"57299.10"},{"label":"Transaction price (shown)","value":"223429.38"},{"label":"Transaction price (shown)","value":"04/15/2026 (date shown)"}],"primary_claim":"On 2026-04-15, Travere Therapeutics, Inc. filed SEC Form 144 (accession 0001950047-26-003477).","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Travere Therapeutics, Inc. (TVTX) filed a Form 144 on 2026-04-15. The filing includes reporting-owner information for Jula Inrig and lists multiple transactions involving common stock with dates in 2026 and share/price figures shown in the document text.","topics":["SEC Form 144","insider sale/disposition notice","common stock","reporting owner","Travere Therapeutics"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Travere Therapeutics, Inc. \u00b7 Filed 20260415","ticker":"TVTX","tickers":["TVTX"],"title":"TVTX filed 144","url":"https://www.sec.gov/Archives/edgar/data/1438533/0001950047-26-003477.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel